Posted by Michael Wonder on 20 Jun 2020
Plakous Therapeutics receives rare paediatric disease and orphan drug designations for Protego-PDTM for the prevention of necrotising enterocolitis
18 June 2020 - Plakous Therapeutics has been granted orphan drug and rare paediatric disease designations for its human placental extract, Protego-PDTM, for the prevention of necrotizing enterocolitis in early preterm infants.
Necrotizing enterocolitis is caused by inflammation and lack of development of the intestine and is observed in very low birth weight babies, those babies born weighing less than three pounds.
